New Vital Signs, Inc. was founded with the mission to revolutionize patient monitoring through innovative, non-invasive wearable sensor technology. The company's core product, Dynamic Respiratory Impedance Volume Evaluation (DRIVE), measures changes in bioimpedance of a patient's limb as they breathe, providing doctors with critical insights into fluid status or intravascular volume. This technology aims to enable earlier intervention and improve patient outcomes by detecting physiological changes sooner than traditional vital signs.

Notable affiliated individuals include experts in biomedical engineering and healthcare innovation, though specific names are not provided. The company has attracted interest from investors focused on cutting-edge medical technologies. Key achievements include the development and ongoing refinement of the DRIVE device, positioning New Vital Signs as a leader in the field of advanced patient monitoring. The overall impact of their work promises significant advancements in early detection and management of serious illnesses, potentially transforming patient care standards globally.